Re­gen­eron heads to­ward FDA fil­ing for mul­ti­ple myelo­ma bis­pe­cif­ic, set­ting up show­down with J&J, Pfiz­er: #ASH23

Near­ly half of the pa­tients who re­ceived an ex­per­i­men­tal mul­ti­ple myelo­ma treat­ment de­vel­oped by Re­gen­eron in a clin­i­cal study saw signs of their can­cer com­plete­ly dis­ap­pear, ac­cord­ing to re­sults re­port­ed by the com­pa­ny Thurs­day morn­ing.

Re­gen­eron said it ex­pects to com­plete a reg­u­la­to­ry fil­ing to the FDA in the com­ing weeks based on the da­ta shared ahead of the Amer­i­can So­ci­ety of Hema­tol­ogy’s an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER